The U.S. Can Lower Drug Prices Without Sacrificing Innovation
https://www.commonwealthfund.org/blog/2021/us-can-lower-drug-prices-without-sacrificing-innovation
https://www.commonwealthfund.org/blog/2021/us-can-lower-drug-prices-without-sacrificing-innovation
Dark Magic: Drug Companies and The Art of Deception
https://www.forbes.com/sites/robertpearl/2023/09/20/dark-magic-drug-companies-and-the-art-of-deception/
https://www.forbes.com/sites/robertpearl/2023/09/20/dark-magic-drug-companies-and-the-art-of-deception/
It’s the Patents, Stupid — Why Drugs Cost So Much in the U.S.
https://www.commonwealthfund.org/publications/podcast/2022/feb/its-the-patents-stupid-why-drugs-cost-so-much-in-us
https://www.commonwealthfund.org/publications/podcast/2022/feb/its-the-patents-stupid-why-drugs-cost-so-much-in-us
How a Drug Company Made $114 Billion by Gaming the
U.S. Patent System
https://www.nytimes.com/2023/01/28/business/humira-abbvie-monopoly.html
AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. The monopoly is about to end.
https://www.nytimes.com/2023/01/28/business/humira-abbvie-monopoly.html
AbbVie for years delayed competition for its blockbuster drug Humira, at the expense of patients and taxpayers. The monopoly is about to end.
Pharma’s expensive gaming of the drug patent system
is successfully countered by the Medicines Patent Pool, which increases global
access and rewards innovation
https://theconversation.com/pharmas-expensive-gaming-of-the-drug-patent-system-is-successfully-countered-by-the-medicines-patent-pool-which-increases-global-access-and-rewards-innovation-189868
https://theconversation.com/pharmas-expensive-gaming-of-the-drug-patent-system-is-successfully-countered-by-the-medicines-patent-pool-which-increases-global-access-and-rewards-innovation-189868
Related:
Healthcare Expenditure – International Comparison
https://www.commonwealthfund.org/publications/issue-briefs/2023/jan/us-health-care-global-perspective-2022
https://www.commonwealthfund.org/publications/issue-briefs/2023/jan/us-health-care-global-perspective-2022
Intellectual Property Laws: Wolves in Sheep’s Clothing
https://promarket.org/intellectual-property-laws-wolves-sheeps-clothing/
Drug Innovation: When Patents Work (and When They Don’t)
https://www.milkenreview.org/articles/drug-innovation-when-patents-work
Our patent system is broken. And it could be stifling innovation.
https://www.washingtonpost.com/outlook/2021/08/08/our-patent-system-is-broken-it-could-be-stifling-innovation/
Are drug patents worth it? | The Economist
https://www.economist.com/business/2021/05/15/are-drug-patents-worth-it
Drug Innovation: When Patents Work (and When They Don’t)
https://www.milkenreview.org/articles/drug-innovation-when-patents-work
Our patent system is broken. And it could be stifling innovation.
https://www.washingtonpost.com/outlook/2021/08/08/our-patent-system-is-broken-it-could-be-stifling-innovation/
Are drug patents worth it? | The Economist
https://www.economist.com/business/2021/05/15/are-drug-patents-worth-it
Tackling Out-of-Control Drug Prices
https://www.milkenreview.org/articles/tackling-out-of-control-drug-prices
https://www.milkenreview.org/articles/tackling-out-of-control-drug-prices
Insulin is way too expensive. California has a
solution: Make its own.
https://www.vox.com/policy-and-politics/23574178/diabetes-insulin-pen-injection-cost-california
https://www.vox.com/policy-and-politics/23574178/diabetes-insulin-pen-injection-cost-california
My take:
Health care and higher education: Key drivers of long-term inflation by Vivekanand Jayakumar | The Hill, 01/31/22
https://thehill.com/opinion/finance/591995-health-care-and-higher-education-key-drivers-of-long-term-inflation/
There is a role for well-thought-out fiscal interventions to boost efficiency and competition in the health care sector. Reforming the U.S. patent system and making the federal government a more effective negotiator that can leverage its role as a large-scale purchaser to attain lower pharmaceutical drug prices are low hanging fruit that can be plucked with bipartisan support if the Big Pharma lobby can be kept at bay.
https://thehill.com/opinion/finance/591995-health-care-and-higher-education-key-drivers-of-long-term-inflation/
There is a role for well-thought-out fiscal interventions to boost efficiency and competition in the health care sector. Reforming the U.S. patent system and making the federal government a more effective negotiator that can leverage its role as a large-scale purchaser to attain lower pharmaceutical drug prices are low hanging fruit that can be plucked with bipartisan support if the Big Pharma lobby can be kept at bay.